Sangamo Biosciences, Inc. (SGMO) Reports In-Line Q4 EPS Loss of $0.12

Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $4.7 million versus the consensus estimate of $3.41 million.

Sangamo Biosciences, Inc. sees FY2012 revenue of $14-$18 million, versus the consensus of $16.23 million.

For earnings history and earnings-related data on Sangamo Biosciences, Inc. (SGMO) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance